NYSE$MDT
Medtronic PLC · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
Medtronic's Q2 2025 financial results demonstrated strong execution and exceeded expectations, leading to raised guidance.
Medtronic reported a strong second quarter in fiscal year 2025, with revenue of $8.4 billion, a 5.3% increase as reported and 5.0% organic. GAAP diluted EPS was $0.99, while non-GAAP diluted EPS reached $1.26. The company has raised its full-year guidance for both organic revenue growth and EPS.
- Revenue increased by 5.3% as reported, reaching $8.4 billion, with 5.0% organic growth.
- GAAP diluted earnings per share (EPS) was $0.99, and non-GAAP diluted EPS was $1.26.
- The company raised its FY25 organic revenue growth and EPS guidance.
- Innovation is driving sustained growth across multiple franchises, including TAVR, PFA, leadless pacemakers, diabetes, spine, and neuromodulation.
Headline financials
Revenue & EPS history
Medtronic · Revenue · Quarterly
$8.4B
Revenue by segment
Medtronic · $8.9B total across 9 segments · Q4 2025
- Cardiac Rhythm & Heart Failure$1.73B—19.5%
- Surgical & Endoscopy$1.71B—19.2%
- Cranial & Spinal Technologies$1.34B—15.1%
- Structural Heart & Aortic$944M—10.6%
- Specialty Therapies$759M—8.5%
- Diabetes$728M—8.2%
- Coronary & Peripheral Vascular$659M—7.4%
- Neuromodulation$520M—5.8%
- Acute Care & Monitoring$503M—5.7%
Forward guidance
Medtronic raised its FY25 organic revenue growth guidance to 4.75% to 5% and non-GAAP EPS guidance to $5.44 to $5.50.
Tailwinds
- FY25 organic revenue growth guidance raised to 4.75% to 5%.
- FY25 diluted non-GAAP EPS guidance raised to $5.44 to $5.50.
- Expect to report high-single digit adjusted EPS growth in the back half of our fiscal year.
- Focus on underlying margin improvement.
- Innovation driving growth.
Headwinds
- Includes an estimated -5% impact from foreign currency exchange based on recent rates.
- SE year-over-year results were affected by a difficult comparison from prior year supply recovery in Surgical.
- SE results were affected by a difficult comparison from prior year increased sequentially.
- Cardiac Ablation Solutions had flat results as strong growth of the PulseSelect™ pulsed field ablation (PFA) system offset declines in cryoablation.
- Other revenue decreased (38.9)%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
-0.2%
Avg return
Earnings day
-0.0%
Avg return
5 days after
-1.4%
Avg return
30 days after
57%
37 / 65 earnings
Positive
+6.2%
Q1 2019
Best reaction
-7.3%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -2.8% | -2.6% | -12.7% | |
| Q2 2026 | +3.9% | +5.1% | +2.3% | |
| Q1 2026 | -3.1% | -0.1% | +3.0% | |
| Q4 2025 | -2.2% | -6.6% | -0.0% | |
| Q3 2025 | -7.3% | -3.1% | -1.7% | |
| Q2 2025 | -4.0% | -1.6% | -8.7% | |
| Q1 2025 | +3.2% | +4.2% | +5.5% | |
| Q4 2024 | -4.0% | -4.4% | -4.8% | |
| Q3 2024 | +1.8% | +1.5% | -1.2% | |
| Q2 2024 | +4.3% | +5.1% | +9.0% | |
| Q1 2024 | +2.5% | +0.7% | -1.4% | |
| Q4 2023 | -6.9% | -5.7% | -0.0% | |
| Q3 2023 | +0.4% | -1.5% | -8.5% | |
| Q2 2023 | -4.0% | -3.9% | -6.3% | |
| Q1 2023 | -4.1% | -3.9% | -10.2% | |
| Q4 2022 | -6.1% | -5.1% | -14.5% | |
| Q3 2022 | +2.4% | +5.2% | +5.7% | |
| Q2 2022 | -2.1% | -5.0% | -12.0% | |
| Q1 2022 | +4.7% | +4.1% | +1.7% | |
| Q4 2021 | +0.3% | -0.8% | +2.8% | |
| Q3 2021 | +2.6% | +1.1% | +0.7% | |
| Q2 2021 | +2.1% | +3.3% | +2.8% | |
| Q1 2021 | +3.9% | +7.7% | +1.1% | |
| Q4 2020 | -3.4% | -0.9% | -4.3% | |
| Q3 2020 | -3.0% | -3.5% | -32.5% | |
| Q2 2020 | +0.5% | -0.4% | +2.0% | |
| Q1 2020 | +3.5% | +1.8% | +6.6% | |
| Q4 2019 | +4.8% | +2.9% | +12.0% | |
| Q3 2019 | +0.6% | +1.6% | -0.2% | |
| Q2 2019 | +2.9% | +1.8% | -0.5% | |
| Q1 2019 | +6.2% | +6.1% | +8.3% | |
| Q4 2018 | +1.2% | +0.2% | +1.8% | |
| Q3 2018 | -3.1% | -3.5% | -6.2% | |
| Q2 2018 | +4.4% | +5.5% | +3.3% | |
| Q1 2018 | -4.5% | -5.3% | -4.8% | |
| Q4 2017 | +0.5% | +0.2% | +5.3% | |
| Q3 2017 | +0.9% | +2.7% | +2.5% | |
| Q2 2017 | -6.0% | -6.3% | -11.0% | |
| Q1 2017 | -0.1% | +0.2% | +1.2% | |
| Q4 2016 | -1.4% | +1.5% | +6.2% | |
| Q3 2016 | -3.6% | — | — | |
| Q2 2016 | +2.7% | — | — | |
| Q1 2016 | -3.6% | — | — | |
| Q4 2015 | +0.2% | — | — | |
| Q3 2015 | +4.3% | — | — | |
| Q2 2015 | +3.7% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | -1.2% | — | — | |
| Q2 2014 | -2.4% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q4 2013 | +3.3% | — | — | |
| Q3 2013 | -5.0% | — | — | |
| Q2 2013 | +1.6% | — | — | |
| Q1 2013 | +1.2% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +2.0% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | -3.2% | — | — | |
| Q4 2011 | +1.5% | — | — | |
| Q3 2011 | +1.4% | — | — | |
| Q2 2010 | -0.2% | — | — | |
| Q1 2010 | +1.5% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2009 | +0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro